The Testing Evidence for Using Fenbendazole for Treating Lung Cancer

Executive Summary

• This article covers the evidence I could find for Fenbendazole as a treatment for Lung Cancer.

Introduction

This article provides an overview covering the evidence for Fenbendazole and related drugs versus Lung Cancer.

Many articles on this website cover the evidence for the benefits of Fenbendazole for cancer. But the question of which specific cancers Fenbendazole has been proven effective is a constant source of questions.

The most common Benzimidazoles are Fenbendazole, Mebendazole and Albendazole. In our analysis, we include research for all three drugs together in articles as they are very similar to one another and it improves the ability to tie together different studies. You may see the following terms/acronyms used.

• FZ or FBZ means Fenbendazole
• MBZ means Mebendazole
• AZ means Albendazole

Cancer Type #1: Lung Cancer

The following quote is from the article Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer.

Emerging studies have reported the potential anticancer activity of benzimidazole-based anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the anticancer activity of BBA is unclear. Therefore, in the current study, network pharmacology and molecular docking-based approach were used to explore the potential molecular mechanism for the treatment of LC. The potential targets for BBA were obtained from multiple databases including SwissTargetPrediction, Drug Bank, Therapeutic Target Database, and Comparative Toxicogenomics Database while LC targets were collected from DisGeNet gene discovery platform, Integrated Genomic Database of NSCLC, Catalogue of Somatic Mutations in Cancer and Online Mendelian Inheritance in Man database. Protein-protein interaction (PPI) diagram of common targets was constructed using STRING online platform. Topological analysis was performed using Cytoscape and gene enrichment analysis was conducted using FunRich software. Highest degree targets were then confirmed using molecular docking and molecular dynamics simulations.

That was the method employed, now here is the outcome.

The BBA were prioritized according to their S scores, with ricobendazole ranking highest followed by flubendazole, fenbendazole, mebendazole, triclabendazole, albendazole, oxibendazole, parbendazole, thiabendazole and oxfendazole. The potential targets of BBA identified using topological analysis and molecular docking were found to be CCND1 (cyclin D1), EGFR (Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase), PTGS2 (Prostaglandin-endoperoxide synthase), and SRC (Proto-oncogene tyrosine-protein kinase). Furthermore, molecular dynamics confirmed that CCND1 and EGFR are the potential targets of ricobendazole for the treatment of LC. BBA can be further explored as a therapeutic strategy for the treatment of lung cancer under in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma.

Of these drugs, fendbendazole came in second after flubendazole. Interestingly these other drugs are not generally available.

The following quote is from the article Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

MBZ and other benzimidazoles seem to target cancer cells preferentially over normal cells, and this may suggest a favorable therapeutic index for in vivo applications. In vitro, MBZ displayed a slightly higher IC50 in mouse astrocytes, compared with those in various GBM cell lines, ranging point eleven point 31 μM. In addition, our two different GBM animal models showed survival benefit for MBZ with minimal toxicity. Several other studies have shown in vivo success with benzimidazoles against cancers, including non–small cell lung cancer, adrenocortical carcinoma, leukemia, and colorectal cancer. There is evidence that MBZ’s mode of action in lung cancer cells involves prevention of polymerization of tubulin.

The following quote is from the article The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.

Microtubules have a critical role in cell division, and consequently various microtubule inhibitors have been developed as anticancer drugs. In this study, we assess mebendazole (MZ), a microtubule-disrupting anthelmintic that exhibits a potent antitumor property both in vitro and in vivo. Treatment of lung cancer cell lines with MZ caused mitotic arrest, followed by apoptotic cell death with the feature of caspase activation and cytochrome c release. MZ induces abnormal spindle formation in mitotic cancer cells and enhances the depolymerization of tubulin, but the efficacy of depolymerization by MZ is lower than that by nocodazole.

Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice. We speculate that tumor cells may be defective in one mitotic checkpoint function and sensitive to the spindle inhibitor MZ. Abnormal spindle formation may be the key factor determining whether a cell undergoes apoptosis, whereas strong microtubule inhibitors elicit toxicity even in normal cells.

The following quote is from the article Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness.

We expanded our preclinical models by orthotopically implanting a TNBC patient-derived xenograft (PDX), HCI-001, in NSG mice. Following 8 weeks of growth, the primary tumors reached an average tumor volume of ~ 150 mm3 (Additional file 2: Fig. S3F, G). The mice were then randomized into two treatment groups which were dosed 4 times per week: sesame oil as a vehicle gavage (Con, N = 8) or 30 mg/kg MBZ in sesame oil gavage (thirty mg/kg; N = nine). After two weeks of treatment, there was no decrease in the size of tumors for the MBZ group nor a reduction of tumor weight). However, we did observe a twofold decrease in metastatic burden in the lung. We observed a twofold reduction in lung nodules in mice treated with thirty mg per kg MBZ compared to mice given vehicle control.

At the endpoint of the experiment, we extracted genomic DNA from mouse lungs and livers to measure metastatic spread using qPCR to quantify human HK2 DNA content. Mice treated with 215 ppm MBZ feed had significantly reduced lung and no detectable liver metastases.

To rule out the effect of primary tumor size contributing to the difference in metastasis, we normalized HK2 DNA content by individual tumor weight and compared it to the mean of the control group. The results demonstrated that MBZ reduces lung metastasis to a greater extent than it inhibits tumor growth and MBZ completely abolishes liver metastases.

We did observe a twofold decrease in metastatic burden in the lung. We observed a twofold reduction in lung nodules in mice treated with thirty mg/kg MBZ compared to mice given vehicle control). The results highlight the ability of MBZ to reduce lung metastases in a TNBC PDX model, which has clinically relevant implications since PDX models closely match patients’ therapeutic responses.

Our preclinical studies demonstrated that the anthelminthic, MBZ, decreased the growth of TNBC and significantly abrogated lung metastasis while eliminating liver metastases. We showed that MBZ decreased TNBC cell proliferation through previously described mechanisms of action, including G two per M cell cycle arrest and apoptosis. Using RNA sequencing, we discovered that MBZ also reduces ITGβ4 expression and previous studies have linked ITGβ4 expression with increased metastasis.

The Multiple Mechanisms by Which Fenbendazole Works Against Cancer

There are many ways in which Fenbendazole works against cancer including.

• Reducing metastasis
• Increase autophagy
• Increase cancer cell death or apoptosis
• and much more

This topic is covered in the article By How Many Different Mechanisms Does Fenbendazole Fight Cancer?

Conclusion

There is ample evidence that Fenbendazole is helpful against many different types of cancers. It is unlikely that these are the only cancers for which Fenbendazole is effective, but the studies we have found so far show that Fenbendazole works to combat and prevent it. Fenbendazole is an immuno-modulator, so it has beneficial effects not only for cancer — as one of the mechanisms of how Fenbendazole works is improving the immune system, which means it improves the immune system against cancer as well as other diseases.

Regarding the dosage and sourcing of Fenbendazole, see the article On the Topic of Fenbendazole Dosage and Sourcing.

Why Are Anti-Parasitic Drugs Effective Against Cancer?

To understand why this class of drugs works against cancer, see the article The Mechanism of How Anti-Parasitic Drugs Work to Mitigate Cancer.

• We have Ivermectin dosage calculators based on research studies and for all the different uses of Ivermectin.
• We are the only web source offering an Ivermectin dosage calculator in addition to different dosage estimates for different cancer types.
• All of our calculators are easy to use (see our dosage calculator listing). Each person enters their personalized information into the calculator and receives our recommended extensively researched dosage estimate automatically and immediately calculated.
• We also cover the broader problems with dosage calculation in medicine at the article The Problem With Dosage Calculation in Medicine, as this is an issue much larger than for one drug. 

Our Recommended Source of Supply

Our approved source for Febendazole and Mebendazole is Summit Products. This source makes Ivermectin much easier to obtain, and Summit Products developed that subsite only to sell the Ivermectin that passed our bioequivalence testing. (which you can read about here)